Aspen Neuroscience prices Parkinson’s cell-therapy IPO
Aspen Neuroscience priced its initial public offering at $15 per share for 9,375,000 shares, with expected gross proceeds of approximately $140.6 million before underwriting discounts and commissions. The Nasdaq listing is scheduled for October 30, 2026, and the financing is slated to settle on November 2, 2026, provided customary conditions are met. Underwriters also received a 30-day option for up to 1,406,250 additional shares.
Why it matters
The IPO gives Aspen Neuroscience gross funding for development of its Parkinson’s cell-therapy programs and introduces ASPE as a newly listed security. The additional-share option could increase the proceeds and share count if exercised.
Key facts
- 1Aspen Neuroscience sold 9,375,000 common shares at $15.00 each. investing.com
- 2The company expects approximately $140.6 million in gross proceeds before underwriting discounts and commissions. investing.com
- 3Trading is scheduled to begin on The Nasdaq Global Select Market on October 30, 2026. stocktitan.net
- 4The offering is scheduled to settle on November 2, 2026, subject to customary closing conditions. stocktitan.net
- 5Underwriters may purchase up to an additional 1,406,250 shares during a 30-day option period. investing.com
Open questions
- Material 2 reports an IPO price of $14.95 per share, while the other event materials report $15 per share or $15.00 per share for the same offering.
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.